Erythropoietin long-acting - Hanmi Pharmaceutical

Drug Profile

Erythropoietin long-acting - Hanmi Pharmaceutical

Alternative Names: HM10760A; LAPS-EPO; Long-acting erythropoietin - Hanmi

Latest Information Update: 20 Apr 2016

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antianaemics; Erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Anaemia

Most Recent Events

  • 30 Nov 2009 Phase-I clinical trials in Anaemia in South Korea (IV)
  • 31 Oct 2009 Phase-I clinical trials in Anaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top